Literature DB >> 21973089

Quantitative real-time PCR and the (1→3)-β-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization.

Y Matsumura1, Y Ito, Y Iinuma, K Yasuma, M Yamamoto, A Matsushima, M Nagao, S Takakura, S Ichiyama.   

Abstract

We evaluated whether quantitative PCR (qPCR) and (1 → 3)-β-d-glucan assays could be used to differentiate Pneumocystis pneumonia (PCP) from Pneumocystis jirovecii colonization in immunocompromised patients with pulmonary infiltrates. A total of 40 bronchoalveolar lavage samples and 107 induced sputum samples from 147 patients who were suspected of having PCP were obtained for PCR detection of P. jirovecii. Diagnoses of definite PCP, probable PCP, pneumonia with P. jirovecii colonization (colonization) and pneumonia without colonization (non-colonization) were made in 11, 42, 15 and 60 patients, respectively. A PCP diagnosis was undetermined in 19 patients. The copy numbers, determined using qPCR, were significantly higher in definite PCP and probable PCP patients than in colonized patients. The area under the receiver-operating characteristic curve (AUC), sensitivity and specificity for discriminating definite PCP from colonization were 0.96, 100.0% and 80.0%, respectively, at a cut-off value of 1300 copies/mL. The values for discriminating probable PCP from colonization were 0.71, 66.7% and 73.3%, respectively, at a cut-off value of 340 copies/mL. β-d-glucan levels were significantly higher in patients with both definite PCP and probable PCP than in colonized patients. The AUC, sensitivity and specificity for discriminating definite PCP were 0.91, 100.0% and 80.0%, respectively, at a cut-off value of 15.6 pg/mL. The values for discriminating probable PCP were 0.78, 76.2% and 73.3%, respectively, at a cut-off value of 6.0 pg/mL. Both qPCR and the β-d-glucan assay displayed high accuracy for discriminating colonization from definite PCP and displayed moderate accuracy for discriminating colonization from probable PCP.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21973089     DOI: 10.1111/j.1469-0691.2011.03605.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  30 in total

1.  Performances of Four Real-Time PCR Assays for Diagnosis of Pneumocystis jirovecii Pneumonia.

Authors:  Milène Sasso; Elsa Chastang-Dumas; Sophie Bastide; Sandrine Alonso; Catherine Lechiche; Nathalie Bourgeois; Laurence Lachaud
Journal:  J Clin Microbiol       Date:  2015-12-30       Impact factor: 5.948

Review 2.  Molecular and nonmolecular diagnostic methods for invasive fungal infections.

Authors:  Marios Arvanitis; Theodora Anagnostou; Beth Burgwyn Fuchs; Angela M Caliendo; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Impact of HIV Infection Status on Interpretation of Quantitative PCR for Detection of Pneumocystis jirovecii.

Authors:  M Louis; J Guitard; M Jodar; T Ancelle; D Magne; O Lascols; C Hennequin
Journal:  J Clin Microbiol       Date:  2015-10-14       Impact factor: 5.948

Review 4.  Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches.

Authors:  Marjorie Bateman; Rita Oladele; Jay K Kolls
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

5.  Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-β-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization.

Authors:  Céline Damiani; Solène Le Gal; Cécilia Da Costa; Michèle Virmaux; Gilles Nevez; Anne Totet
Journal:  J Clin Microbiol       Date:  2013-07-31       Impact factor: 5.948

6.  (1-3)-beta-D-glucan in association with lactate dehydrogenase as biomarkers of Pneumocystis pneumonia (PcP) in HIV-infected patients.

Authors:  F Esteves; C-H Lee; B de Sousa; R Badura; M Seringa; C Fernandes; J F Gaspar; F Antunes; O Matos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-03       Impact factor: 3.267

7.  Serum and bal beta-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients.

Authors:  D Salerno; D Mushatt; L Myers; Y Zhuang; N de la Rua; E J Calderon; D A Welsh
Journal:  Respir Med       Date:  2014-11       Impact factor: 3.415

8.  Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia.

Authors:  Michael J Linke; Alan Ashbaugh; Margaret S Collins; Keeley Lynch; Melanie T Cushion
Journal:  Infect Immun       Date:  2013-01-14       Impact factor: 3.441

9.  Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study.

Authors:  Florence Robert-Gangneux; Sorya Belaz; Matthieu Revest; Pierre Tattevin; Stéphane Jouneau; Olivier Decaux; Sylviane Chevrier; Yves Le Tulzo; Jean-Pierre Gangneux
Journal:  J Clin Microbiol       Date:  2014-07-09       Impact factor: 5.948

Review 10.  Narrative review of the relationship between COVID-19 and PJP: does it represent coinfection or colonization?

Authors:  Woon H Chong; Biplab K Saha; Amit Chopra
Journal:  Infection       Date:  2021-05-31       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.